Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 3, 2006, Pages 184-192

  Park, Joong Won ^a   Jung, Eun Park ^a   Jung, Ahn Lee ^a   Lee, Chang Woo ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cyclooxygenase 2; Growth inhibition; Hepatocellular carcinoma; siRNA

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; ENZYMOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPORATION; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; NITROBENZENES; RNA, SMALL INTERFERING; SULFONAMIDES; TRANSFECTION;

EID: 29544432032     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0060-x     Document Type: Article

References (31)

1. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC (2003) Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res 63:728-734
2. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T et al (2002) Expressions of cyclooxygenase-2 and prostaglandin E receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8:1157-1167
3. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7:1410-1418
4. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553
5. Callejas NA, Castrillo A, Bosca L, Martin-Sanz P (1999) Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 indueced by lipopolysaccharide and peroxisomal proliferators. J Phar Exp Ther 288:1235-1241
6. Cheng J, Imanishi H, Amuro Y, Hada T (2002a) NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 99(5):755-761
7. Cheng ASL, Chan HLY, Leung NWY, Liew CT, To KF, Lai PBS, Sung JJY (2002b) Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. Aliment Pharmacol Ther 16:251-260
8. Chiou SK, Tanigawa T, Akahoshi T, Abdelkarim B, Jones MK, Tarnawski AS (2005) Survivin: a novel target for indomethacin-induced gastric injury. Gastroenterology 128:63-73
9. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, Siegert A et al (2003) Induction of G0/G1 cell cycle arrest in ovarian carcinoma 1cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 22:8653-8661
10. Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A, et al. (2002) The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35:843-852
11. Fosslien E (2000) Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37(5):431-502
12. Gasparini G, Longo R, Sarmiento R, Morabito A (2003) Inhibitors of cyclo-ocygenase 2: a new class of anticancer agents. Lancet Oncol 4:605-615
13. Goodsell DS (2000) The molecular perspective: cyclooxygenase-2. Stem Cells 18:227-229
14. Hannon GJ (2002) RNA interference. Nature 418:244-251
15. Hassoun Z, Gores GJ (2003) Treatment of hepatocellular carcinoma. Clin Gastroenterol Hepatol 1:10-18
16. Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, et al. (2001) Differential expression of cyclooxygenase-2 in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34:638-650
17. Hu KQ (2002) Rationale and feasibility of Chemoprevention of hepatocellular carcinoma by cycloocygenase-2 inhibitors. J Lab Clin Med 139:234-243
18. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, Dienes HP, et al. (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36(4 Pt 1):885-894
19. Kern MA, Schoneweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU, Dienes HP, et al. (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 25(7):1193-1199
20. Koga H (2003) Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer 98:661-667
21. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, et al. (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma; relevance to tumor dedifferentiation. Hepatology 29:688-696
22. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, Mira E, Iniguez MA, Fresno M, Martinez-A C et al (2002) The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 110:1831-1838
23. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T (2003) Cyclooxygenase-2 promotes hepatocellular caricoma cell growth through AKT activation: evidence of AKT inhibition in celecoxib-induced apoptosis. Hepatology 38:756-768
24. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ (2002) COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35:552-559
25. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, et al. (2001) Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7:1325-1332
26. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, Ohrr H, et al. (2002) Cancer incidence in Korea. Cancer Res Treatment 34:405-408
27. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, et al. (1999) Cyclooxygease-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46:407-412
28. Shuey DJ, McCallus DE, Giordano T (2002) RNAi: gene-silencing in therapeutic intervention. Drug Discov Today 7:1040-1046
29. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA (2002) Altered expression of E-caderin in hepatocellular carcinoma: correlation with genetic alterations, beta-catenin expression, and clinical features. Hepatology 36:692-701
30. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916
31. World Health Organization (2003) World cancer report 2003, IARC Press, Lyon